Semaglutide Treatment On Coronary Progression

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT03985384

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03985384
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03985384. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-30 (actual); primary completion 2022-12-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide Treatment On Coronary Progression
Acronym
STOP
Intervention (Drug)
Semaglutide 2 MG/1.5 ML Subcutaneous Solution
Intervention (Drug)
Placebo
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (class: other)

Record details

Record id
cardio:ct-nct03985384
Content hash
401212d22d9f10deb51cba66729931d784a2b6bc32b030ad28a08cff85acd3fc